Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

Daisuke Nobuoka, Yutaka Motomura, Hirofumi Shirakawa, Toshiaki Yoshikawa, Toshimitsu Kuronuma, Mari Takahashi, Kohei Nakachi, Hiroshi Ishii, Junji Furuse, Naoto Gotohda, Shinichiro Takahashi, Toshio Nakagohri, Masaru Konishi, Taira Kinoshita, Hiroyuki Komori, Hideo Baba, Toshiyoshi Fujiwara, Tetsuya Nakatsura

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy against hepatocellular carcinoma (HCC). In this study, we attempted to compare the induction of the GPC3-specific T-cell-mediated immune response after locoregional therapies in HCC patients and tumor-bearing mice. Twenty-seven HCC patients treated with locoregional therapies, including radiofrequency ablation (RFA), surgical resection and transcatheter arterial chemoembolization (TACE), were prospectively enrolled in this study. Additionally, we performed RFA experiments using a mouse model. GPC3-specific T-cell response was investigated pre-treatment and post-treatment by an interferon-γ enzyme-linked immunospot assay using peripheral blood mononuclear cells from HCC patients and lymph node cells from tumor-bearing mice. Circulating GPC3-specific cytotoxic T lymphocytes (CTLs) were increased in 5 of 9 patients after RFA and in 4 of 9 patients after TACE, but in only 1 of 9 patients after surgical resection. All 7 patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific CTLs after RFA or TACE, whereas none of the 7 patients did after surgical resection. The number of increased GPC3-specific CTLs after RFA was significantly larger than that after surgical resection (P=0.023). Similarly, the frequency of GPC3-specific CTLs after RFA was significantly greater than that after surgical resection in the mouse model (P=0.049). We validated for the first time the stronger effect on the immune system brought by RFA compared with surgical resection for HCC patients and tumor-bearing mice. Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalInternational Journal of Oncology
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Glypicans
Cytotoxic T-Lymphocytes
Hepatocellular Carcinoma
Peptides
Immunotherapy
T-Lymphocytes
Therapeutics
Enzyme-Linked Immunospot Assay
Neoplasms
Carcinoembryonic Antigen
Interferons
Immune System
Blood Cells
Lymph Nodes

Keywords

  • Cytotoxic T lymphocyte
  • Glypican-3
  • Hepatocellular carcinoma
  • Immunotherapy
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nobuoka, D., Motomura, Y., Shirakawa, H., Yoshikawa, T., Kuronuma, T., Takahashi, M., ... Nakatsura, T. (2012). Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 40(1), 63-70. https://doi.org/10.3892/ijo.2011.1202

Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. / Nobuoka, Daisuke; Motomura, Yutaka; Shirakawa, Hirofumi; Yoshikawa, Toshiaki; Kuronuma, Toshimitsu; Takahashi, Mari; Nakachi, Kohei; Ishii, Hiroshi; Furuse, Junji; Gotohda, Naoto; Takahashi, Shinichiro; Nakagohri, Toshio; Konishi, Masaru; Kinoshita, Taira; Komori, Hiroyuki; Baba, Hideo; Fujiwara, Toshiyoshi; Nakatsura, Tetsuya.

In: International Journal of Oncology, Vol. 40, No. 1, 01.2012, p. 63-70.

Research output: Contribution to journalArticle

Nobuoka, D, Motomura, Y, Shirakawa, H, Yoshikawa, T, Kuronuma, T, Takahashi, M, Nakachi, K, Ishii, H, Furuse, J, Gotohda, N, Takahashi, S, Nakagohri, T, Konishi, M, Kinoshita, T, Komori, H, Baba, H, Fujiwara, T & Nakatsura, T 2012, 'Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes', International Journal of Oncology, vol. 40, no. 1, pp. 63-70. https://doi.org/10.3892/ijo.2011.1202
Nobuoka, Daisuke ; Motomura, Yutaka ; Shirakawa, Hirofumi ; Yoshikawa, Toshiaki ; Kuronuma, Toshimitsu ; Takahashi, Mari ; Nakachi, Kohei ; Ishii, Hiroshi ; Furuse, Junji ; Gotohda, Naoto ; Takahashi, Shinichiro ; Nakagohri, Toshio ; Konishi, Masaru ; Kinoshita, Taira ; Komori, Hiroyuki ; Baba, Hideo ; Fujiwara, Toshiyoshi ; Nakatsura, Tetsuya. / Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. In: International Journal of Oncology. 2012 ; Vol. 40, No. 1. pp. 63-70.
@article{ccf5192ad7f3460fa685b464c024e996,
title = "Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes",
abstract = "Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy against hepatocellular carcinoma (HCC). In this study, we attempted to compare the induction of the GPC3-specific T-cell-mediated immune response after locoregional therapies in HCC patients and tumor-bearing mice. Twenty-seven HCC patients treated with locoregional therapies, including radiofrequency ablation (RFA), surgical resection and transcatheter arterial chemoembolization (TACE), were prospectively enrolled in this study. Additionally, we performed RFA experiments using a mouse model. GPC3-specific T-cell response was investigated pre-treatment and post-treatment by an interferon-γ enzyme-linked immunospot assay using peripheral blood mononuclear cells from HCC patients and lymph node cells from tumor-bearing mice. Circulating GPC3-specific cytotoxic T lymphocytes (CTLs) were increased in 5 of 9 patients after RFA and in 4 of 9 patients after TACE, but in only 1 of 9 patients after surgical resection. All 7 patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific CTLs after RFA or TACE, whereas none of the 7 patients did after surgical resection. The number of increased GPC3-specific CTLs after RFA was significantly larger than that after surgical resection (P=0.023). Similarly, the frequency of GPC3-specific CTLs after RFA was significantly greater than that after surgical resection in the mouse model (P=0.049). We validated for the first time the stronger effect on the immune system brought by RFA compared with surgical resection for HCC patients and tumor-bearing mice. Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC.",
keywords = "Cytotoxic T lymphocyte, Glypican-3, Hepatocellular carcinoma, Immunotherapy, Radiofrequency ablation",
author = "Daisuke Nobuoka and Yutaka Motomura and Hirofumi Shirakawa and Toshiaki Yoshikawa and Toshimitsu Kuronuma and Mari Takahashi and Kohei Nakachi and Hiroshi Ishii and Junji Furuse and Naoto Gotohda and Shinichiro Takahashi and Toshio Nakagohri and Masaru Konishi and Taira Kinoshita and Hiroyuki Komori and Hideo Baba and Toshiyoshi Fujiwara and Tetsuya Nakatsura",
year = "2012",
month = "1",
doi = "10.3892/ijo.2011.1202",
language = "English",
volume = "40",
pages = "63--70",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

AU - Nobuoka, Daisuke

AU - Motomura, Yutaka

AU - Shirakawa, Hirofumi

AU - Yoshikawa, Toshiaki

AU - Kuronuma, Toshimitsu

AU - Takahashi, Mari

AU - Nakachi, Kohei

AU - Ishii, Hiroshi

AU - Furuse, Junji

AU - Gotohda, Naoto

AU - Takahashi, Shinichiro

AU - Nakagohri, Toshio

AU - Konishi, Masaru

AU - Kinoshita, Taira

AU - Komori, Hiroyuki

AU - Baba, Hideo

AU - Fujiwara, Toshiyoshi

AU - Nakatsura, Tetsuya

PY - 2012/1

Y1 - 2012/1

N2 - Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy against hepatocellular carcinoma (HCC). In this study, we attempted to compare the induction of the GPC3-specific T-cell-mediated immune response after locoregional therapies in HCC patients and tumor-bearing mice. Twenty-seven HCC patients treated with locoregional therapies, including radiofrequency ablation (RFA), surgical resection and transcatheter arterial chemoembolization (TACE), were prospectively enrolled in this study. Additionally, we performed RFA experiments using a mouse model. GPC3-specific T-cell response was investigated pre-treatment and post-treatment by an interferon-γ enzyme-linked immunospot assay using peripheral blood mononuclear cells from HCC patients and lymph node cells from tumor-bearing mice. Circulating GPC3-specific cytotoxic T lymphocytes (CTLs) were increased in 5 of 9 patients after RFA and in 4 of 9 patients after TACE, but in only 1 of 9 patients after surgical resection. All 7 patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific CTLs after RFA or TACE, whereas none of the 7 patients did after surgical resection. The number of increased GPC3-specific CTLs after RFA was significantly larger than that after surgical resection (P=0.023). Similarly, the frequency of GPC3-specific CTLs after RFA was significantly greater than that after surgical resection in the mouse model (P=0.049). We validated for the first time the stronger effect on the immune system brought by RFA compared with surgical resection for HCC patients and tumor-bearing mice. Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC.

AB - Glypican-3 (GPC3), a carcinoembryonic antigen, is an ideal target for anticancer immunotherapy against hepatocellular carcinoma (HCC). In this study, we attempted to compare the induction of the GPC3-specific T-cell-mediated immune response after locoregional therapies in HCC patients and tumor-bearing mice. Twenty-seven HCC patients treated with locoregional therapies, including radiofrequency ablation (RFA), surgical resection and transcatheter arterial chemoembolization (TACE), were prospectively enrolled in this study. Additionally, we performed RFA experiments using a mouse model. GPC3-specific T-cell response was investigated pre-treatment and post-treatment by an interferon-γ enzyme-linked immunospot assay using peripheral blood mononuclear cells from HCC patients and lymph node cells from tumor-bearing mice. Circulating GPC3-specific cytotoxic T lymphocytes (CTLs) were increased in 5 of 9 patients after RFA and in 4 of 9 patients after TACE, but in only 1 of 9 patients after surgical resection. All 7 patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific CTLs after RFA or TACE, whereas none of the 7 patients did after surgical resection. The number of increased GPC3-specific CTLs after RFA was significantly larger than that after surgical resection (P=0.023). Similarly, the frequency of GPC3-specific CTLs after RFA was significantly greater than that after surgical resection in the mouse model (P=0.049). We validated for the first time the stronger effect on the immune system brought by RFA compared with surgical resection for HCC patients and tumor-bearing mice. Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC.

KW - Cytotoxic T lymphocyte

KW - Glypican-3

KW - Hepatocellular carcinoma

KW - Immunotherapy

KW - Radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84455174508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455174508&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1202

DO - 10.3892/ijo.2011.1202

M3 - Article

C2 - 21922136

AN - SCOPUS:84455174508

VL - 40

SP - 63

EP - 70

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -